Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56

Benzinga · 2d ago
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $56.